Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SSY Group's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 169.83.
SSY Group's Days Inventory for the
six
months ended in Dec. 2025 was 182.91.
SSY Group's Days Payable for the
six
months ended in Dec. 2025 was 51.35.
Therefore, SSY Group's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 301.39.
SSY Group (OTCPK:LJUIF) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
SSY Group Cash Conversion Cycle Related Terms
SSY Group Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for SSY Group's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SSY Group's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SSY Group Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SSY Group's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where SSY Group's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
SSY Group's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SSY Group (LJUIF) has a Cash Conversion Cycle of 301.39 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on SSY Group and its competitors.
Is SSY Group's Cash Conversion Cycle too high?
SSY Group's current Cash Conversion Cycle is 301.39. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. SSY Group's value of 301.39 is 106.7% above this industry median. Overall, SSY Group has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does SSY Group's Cash Conversion Cycle compare to ZTS?
SSY Group's Cash Conversion Cycle of 301.39 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. SSY Group's value of 301.39 is 106.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SSY Group's current Cash Conversion Cycle of 301.39 is 106.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on SSY Group and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SSY Group's current Cash Conversion Cycle is 301.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SSY Group stock overvalued right now?
SSY Group (LJUIF) has a current Cash Conversion Cycle of 301.39. The stock's GF Value™ is $0.51, compared to a current price of $0.40 — trading 21.1% below its estimated fair value. The current Cash Conversion Cycle is 301.39 and 106.7% above the Drug Manufacturers industry median of 145.82. SSY Group's overall GF Score™ is 86/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For SSY Group (LJUIF), the current Cash Conversion Cycle is 301.39 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SSY Group (LJUIF) Overvalued in 2026?
Based on GuruFocus' analysis, SSY Group stock appears to be undervalued.
The current stock price of $0.40 is trading 21.1% below its estimated GF Value™ of $0.51.
Key valuation signals for LJUIF:
Cash Conversion Cycle: 301.39
GF Value™: $0.51 vs. price of $0.40 (21.1% below fair value)
Industry Position: 106.7% above the Drug Manufacturers median
No single metric tells the full story. See the LJUIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products. The company derives maximum revenue from PRC.
86GF Score
Get the complete analysis for LJUIF
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LJUIF has been successfully added to your 
